https://scholars.lib.ntu.edu.tw/handle/123456789/496045
標題: | Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus | 作者: | CHIN-HSIAO TSENG | 公開日期: | 2019 | 出版社: | BioScientifica Ltd. | 卷: | 180 | 期: | 6 | 起(迄)頁: | 365-372 | 來源出版物: | European Journal of Endocrinology | 摘要: | Background: Whether metformin might affect the risk of benign nodular goite r in patients with type 2 diabetes mellitus has not been investigated. Methods: Patients with new-onset type 2 diabetes mellitus during 1999-2005 were enrolled from Taiwan's National Health Insurance database. Analyses were conducted in a propensity score matched-pairs of 20,048 ever users and 20,048 never users of metformin. The patients were followed until December 31, 2011, for the incidence of benign nodular goiter. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the propensity score. Results: Among the never users and ever users of metformin, 392 and 221 cases were diagnosed of benign nodular goiter during follow-up, with incidence of 457.88 and 242.45 per 100,000 person-years, respectively. The overall hazard ratio for ever versus never users was 0.527 (95% confidence inte rval: 0.447-0.621). When cumulative duration of metformin therapy was divided into tertiles, the hazard ratios for the first (<25.3 months), second (25.3-57.3 months) and third (>57.3 months) tertiles were 0.815 (0.643-1.034), 0.648 (0.517-0.812) and 0.255 (0.187-0.348), respectively. Sensitivity analyses estimating the overall hazard ratios for p atients enrolled in each specific year from 1999 to 2005 consistently showed a lower risk of benign nodular goiter among users of metformin. Conclusion: Metformin use is associated with a lower risk of benign nodula r goiter in patients with type 2 diabetes mellitus. ? 2019 European Society of Endocrinology Printed in Great Britain. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066163907&doi=10.1530%2fEJE-19-0133&partnerID=40&md5=59aa853972c135266f2e99102529548b https://scholars.lib.ntu.edu.tw/handle/123456789/496045 |
ISSN: | 0804-4643 | DOI: | 10.1530/EJE-19-0133 | SDG/關鍵字: | acarbose; insulin; meglitinide; metformin; pioglitazone; rosiglitazone; sulfonylurea derivative; antidiabetic agent; metformin; aged; Article; benign nodular goiter; cohort analysis; controlled study; diabetic patient; female; follow up; human; incidence; major clinical study; male; national health insurance; nodular goiter; non insulin dependent diabetes mellitus; pharmaceutical care; population research; prescription; priority journal; retrospective study; risk reduction; treatment duration; complication; insulin resistance; middle aged; nodular goiter; non insulin dependent diabetes mellitus; physiology; proportional hazards model; risk factor; Taiwan; very elderly; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Goiter, Nodular; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Proportional Hazards Models; Risk Factors; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。